An updated draft of the BIOSECURE Act introduced on Friday would give U.S. drug manufacturers additional leeway for existing ...

Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, ...

The major biopharma players have promised to increase their investments in France to help boost their respective global ...

Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease ...

A pre-planned analysis revealed patients receiving the vibostolimab-Keytruda coformulation in a late-stage trial had a high ...

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could ...

The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another ...

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central ...

With its first-in-class endothelin and angiotensin II receptor antagonist Filspari, Travere Therapeutics is providing a more ...

Amylyx’s recent decision to withdraw its ALS drug Relyvrio from the market highlights an important business decision for ...

Two of the five fatalities were found to be unrelated to MacroGenics’ investigational antibody-drug conjugate vobra duo, ...

While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how ...